Elia Seguí (@elia_segui) 's Twitter Profile
Elia Seguí

@elia_segui

Medical Oncologist @hospitalclinic | PhD student Translational Genomics @idibaps | Proud @SOLTIyoung member | 🧬 Main focus: IO & breast cancer

ID: 233572875

calendar_today03-01-2011 15:50:03

268 Tweet

495 Takipçi

444 Takip Edilen

Dana-Farber’s Breast Oncology Center (@dfci_breastonc) 's Twitter Profile Photo

#ASCO24 Poster Session | Comprehensive analysis of TROP2, PD-L1, stromal (s)#TILs, and HER2 expression patterns in patients with metastatic HR+HER2- #BreastCancer | Abstract: 1062 | Poster Bd #: 40 Chiara Corti #AnaGarridoCastro Sara Tolaney Nancy Lin, MD Dr. E Mittendorf Rinath Jeselsohn G Curigliano MD PhD

#ASCO24 Poster Session | Comprehensive analysis of TROP2, PD-L1, stromal (s)#TILs, and HER2 expression patterns in patients with metastatic HR+HER2- #BreastCancer | Abstract: 1062 | Poster Bd #: 40  <a href="/CCortiMD/">Chiara Corti</a> #AnaGarridoCastro <a href="/stolaney1/">Sara Tolaney</a> <a href="/nlinmd/">Nancy Lin, MD</a> <a href="/EMittendorfMD/">Dr. E Mittendorf</a> <a href="/RMJesel/">Rinath Jeselsohn</a> <a href="/curijoey/">G Curigliano MD PhD</a>
Elia Seguí (@elia_segui) 's Twitter Profile Photo

Such an inspiring talk by #NiloferAzad on exploratory phase I and II trials for immunotherapy. Amazing faculty here at #MCCRworkshop. I feel so lucky to be here! Hospital Clínic IDIBAPS SOLTI #cancerresearch

Such an inspiring talk by #NiloferAzad on exploratory phase I and II trials for immunotherapy. Amazing faculty here at #MCCRworkshop. I feel so lucky to be here! <a href="/hospitalclinic/">Hospital Clínic</a> <a href="/idibaps/">IDIBAPS</a> <a href="/_SOLTI/">SOLTI #cancerresearch</a>
Aleix Prat #PrecisionOncology (@prat_aleix) 's Twitter Profile Photo

The debate is still out about using doce-carbo vs AC-T in early-stage HER2+ disease, but the evidence is high (check recent JCO below), and de-escalation to non-antracyline is risky without proper selection of patients. We are know even pursuing the use of single taxane

The debate is still out about using doce-carbo vs AC-T in early-stage HER2+ disease, but the evidence is high (check recent JCO below), and de-escalation to non-antracyline is risky without proper selection of patients. We are know even pursuing the use of single taxane
Aleix Prat #PrecisionOncology (@prat_aleix) 's Twitter Profile Photo

📅 Curs 2023-2024 de la Societat Catalano-Balear d'Oncologia 📍 Us espero aquest dimarts 18 a la tarda a Can Caralleu - Sala 3, de 6 a 8 pm, per parlar dels últims Avenços i novetats en oncologia shorturl.at/Zsh09 SCBdOncologia

📅 Curs 2023-2024 de la Societat Catalano-Balear d'Oncologia

📍 Us espero aquest dimarts 18 a la tarda a Can Caralleu - Sala 3, de 6 a 8 pm, per parlar dels últims Avenços i novetats en oncologia

shorturl.at/Zsh09 <a href="/SCBdOncologia/">SCBdOncologia</a>
Elia Seguí (@elia_segui) 's Twitter Profile Photo

#MCCR2024 is not only the best opportunity to learn about clinical research, but also an outstanding occasion to network with international colleagues. I strongly encourage all young oncologists to attend—it's a once-in-a-lifetime experience! Marta Perachino Matteo Lambertini, MD PhD ESMO - Eur. Oncology

#MCCR2024 is not only the best opportunity to learn about clinical research, but also an outstanding occasion to network with international colleagues. I strongly encourage all young oncologists to attend—it's a once-in-a-lifetime experience! <a href="/MartaPerachino/">Marta Perachino</a> <a href="/matteolambe/">Matteo Lambertini, MD PhD</a> <a href="/myESMO/">ESMO - Eur. Oncology</a>
Tomás Pascual (@tomaspascualmd) 's Twitter Profile Photo

I never imagined how fulfilling this would be. Thrilled to announce that our #DEFINITIVEtrial now has an NCT number: NCT06446882. First SIV this summer! 🔗Link clinicaltrials.gov/study/NCT06446…

I never imagined how fulfilling this would be. Thrilled to announce that our #DEFINITIVEtrial now has an NCT number: NCT06446882.

First SIV this summer!

🔗Link clinicaltrials.gov/study/NCT06446…
Aleix Prat #PrecisionOncology (@prat_aleix) 's Twitter Profile Photo

Thank you, Dr. Diletta Favero, for your amazing dedication and responsibility during your rotation at Hospital Clínic 🏥, IDIBAPS 🧬Universitat de Barcelona 🎓! #ClinicCancerCenter I am sure we will keep collaborating! 💪Good luck in your new position in Istituto di Candiolo - FPO IRCCS Italy 🇮🇹!

Thank you, Dr. Diletta Favero, for your amazing dedication and responsibility during your rotation at <a href="/hospitalclinic/">Hospital Clínic</a> 🏥, <a href="/idibaps/">IDIBAPS</a> 🧬<a href="/UniBarcelona/">Universitat de Barcelona</a> 🎓! #ClinicCancerCenter

I am sure we will keep collaborating!

💪Good luck in your new position in <a href="/fpoirccs/">Istituto di Candiolo - FPO IRCCS</a> Italy 🇮🇹!
SOLTIyoung (@soltiyoung) 's Twitter Profile Photo

¡Atención jóvenes oncólogos! ¡Primera beca #SOLTIYoung para asistir al congreso SABCS2024 en San Antonio!✈️ Se cubren inscripción, traslado y manutención. ¡No te pierdas esta oportunidad única!🌍 👉 Abierto a miembros #SOLTIYoung Consulta las bases aquí gruposolti.org/soltiyoung/

¡Atención jóvenes oncólogos! ¡Primera beca #SOLTIYoung para asistir al congreso SABCS2024 en San Antonio!✈️ 

Se cubren inscripción, traslado y manutención.
¡No te pierdas esta oportunidad única!🌍

👉 Abierto a miembros #SOLTIYoung
Consulta las bases aquí gruposolti.org/soltiyoung/
Elia Seguí (@elia_segui) 's Twitter Profile Photo

After 14y of crossing this entrance—first as a med student, then as a resident and fellow—I say bye to the place I’ve called home, where I’ve had some of the best and toughest times with amazing colleagues, now friends. Thank you Hospital Clínic. Off to new adventures in Boston✈️

After 14y of crossing this entrance—first as a med student, then as a resident and fellow—I say bye to the place I’ve called home, where I’ve had some of the best and toughest times with amazing colleagues, now friends. Thank you <a href="/hospitalclinic/">Hospital Clínic</a>. Off to new adventures in Boston✈️